摘要
目的:观察通滞苏润江胶囊联合塞来昔布对早期膝骨关节炎(KOA)患者血清炎症因子和疼痛介质的影响。方法:选择2021年6月-2022年12月期间石家庄市人民医院收治的早期KOA患者80例,采用随机数字表法将患者分为对照组(塞来昔布,40例)和观察组(通滞苏润江胶囊联合塞来昔布,40例)。对比两组疗效、疼痛视觉模拟评分(VAS)、西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评分、炎症因子和疼痛介质。结果:观察组临床总有效率高于对照组(P<0.05)。两组治疗1个月后VAS、WOMAC评分下降,且观察组低于对照组同时间点(P<0.05)。两组治疗1个月后肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)下降,且观察组低于对照组同时间点(P<0.05)。两组治疗1个月后前列腺素E2(PGE2)、P物质(SP)下降,且观察组低于对照组同时间点(P<0.05)。两组不良反应发生率对比未见统计学差异(P>0.05)。结论:塞来昔布和通滞苏润江胶囊联合治疗早期KOA患者,可缓解疼痛,提高临床治疗效果,改善关节功能,同时还可改善血清炎症因子和疼痛介质水平。
Objective:To observe the effects of Tongzhi surunjiang capsules combined with celecoxib on serum inflammatory factors and pain mediators in patients with early knee osteoarthritis(KOA).Methods:80 patients with early KOA who were admitted to Shijiazhuang People's Hospital from June 2021 to December 2022 were selected,and patients were divided into control group(celecoxib,40 cases)and observation group(tongzhi surunjiang capsules combined with celecoxib,40 cases)by random number table method.The efficacy,pain visual analogue scale(VAS),Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC)score,inflammatory factors and pain mediators were compared between two groups.Results:The total effective rate in observation group was higher than that in control group(P<0.05).1 month after treatment,the VAS and WOMAC scores in two groups decreased,and those in observation group were lower than control group at the same time point(P<0.05).1 month after treatment,the levels of tumor necrosis factor-α(TNF-α),interleukin-1β(IL-1β)and interleukin-6(IL-6)in two groups decreased,and those in observation group were lower than control group at the same time point(P<0.05).1 month after treatment,prostaglandin E2(PGE2)and substance P(SP)decreased in two groups,and those in observation group were lower than control group at the same time point(P<0.05).There was no significant difference in the incidence of adverse reactions between two groups(P>0.05).Conclusion:The combination of celecoxib and tongzhi surunjiang capsule in the treatment of early KOA patients can relieve pain,improve the clinical treatment effect,improve joint function,and also improve the levels of serum inflammatory factors and pain mediators.
作者
李洁冰
田振峰
毕伟东
梁丙寅
张弛
张斌
LI Jie-bing;TIAN Zhen-feng;BIWei-dong;LIANG Bing-yin;ZHANG Chi;ZHANG Bin(Department of Orthopedics,Shijiazhuang People's Hospital,Shijiazhuang,Hebei,050000,China)
出处
《现代生物医学进展》
CAS
2024年第3期578-581,485,共5页
Progress in Modern Biomedicine
基金
河北省卫生健康委科研基金项目(20181014)。
关键词
通滞苏润江胶囊
塞来昔布
早期膝骨关节炎
炎症因子
疼痛介质
Tong zhi su run capsules
Celecoxib
Early knee osteoarthritis
Inflammatory factors
Pain mediator
作者简介
李洁冰(1982-),男,硕士,主治医师,研究方向:膝关节骨关节炎的阶梯治疗,E-mail:13931181551@163.com。
